NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb

Posted on by

Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selection LONDON, May 22, 2024 /PRNewswire/ — NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.